What does Hove Pharma do?

Hove Pharma is a pharmacy in Hove. Private Limited, started on 18 November 2019, 1 establishment.

What is the address of Hove Pharma?

The registered office of Hove Pharma is located at Kapelstraat 12, 2540 Hove.

Is Hove Pharma still active?

Yes. According to the CBE (29 October 2026) Hove Pharma is active, legal situation “Normale toestand”, started on 18 November 2019.

Is Hove Pharma registered on Peppol?

Yes, Hove Pharma is registered on the Peppol network with ID 0208:0737798331.

What is the enterprise number of Hove Pharma?

The enterprise number of Hove Pharma is BE0737798331.

When was Hove Pharma founded?

Hove Pharma was founded on 18 November 2019.

Who are the directors of Hove Pharma?

According to the 2025 annual accounts, the directors of Hove Pharma are: JKS Hove BV, APG Management BV.

Is Hove Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 November 2019; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Hove Pharma make in 2025?

Hove Pharma posted a profit after taxes of € 51,083 in financial year 2025.

What is the revenue of Hove Pharma?

As a small company, Hove Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 198,814.

How much does an employee at Hove Pharma earn?

The average wage cost per full-time employee at Hove Pharma was € 57,000 in 2025: staff costs of € 56,990 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Hove Pharma have?

According to the 2025 annual accounts, Hove Pharma has 1 full-time equivalents (FTE).

Does Hove Pharma have a website?

Yes, Hove Pharma has a website at hovepharma.be.

Hove Pharma (Private Limited) - Hove - BE0737798331

Dossier Hove Pharma, printed on 29 October 2026 from databakkes.be/en/0737798331/hove-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Hove Pharma from Hove, company number BE0737798331, closed financial year 2025 with a result of € 51,083 after tax. For that financial year Hove Pharma recorded a gross margin of € 198,814 and equity of € 227,556. Compared with financial year 2024, the result moved from € 32,317 to € 51,083. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.

What it is worth Growing

€ 227,556

▲ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 51,083

▲ 58% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 25,326

▲ 99% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 14,000 paid out

27 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

▲ 0.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 56,990

▲ 96% vs 2024

€ 57,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 450,439

▼ 11% vs 2024

€ 57,108 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 144,347

▲ 47% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 7,730

▲ 90% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 81,566 Gross margin 2022: € 81,566 First fiscal year in the series	€ 132,594 Gross margin 2023: € 132,594 ▲ 63% vs 2022 (€ 81,566) Favourable step	€ 143,467 Gross margin 2024: € 143,467 ▲ 8% vs 2023 (€ 132,594) Favourable step	€ 198,814 Gross margin 2025: € 198,814 ▲ 39% vs 2024 (€ 143,467) Favourable step	▲ 39%
Profit after taxes	€ -59,044 Profit after taxes 2022: € -59,044 First fiscal year in the series	€ 22,547 Profit after taxes 2023: € 22,547 ▲ € 81,591 vs 2022 (€ -59,044) Favourable step	€ 32,317 Profit after taxes 2024: € 32,317 ▲ 43% vs 2023 (€ 22,547) Favourable step	€ 51,083 Profit after taxes 2025: € 51,083 ▲ 58% vs 2024 (€ 32,317) Favourable step	▲ 58%
Equity	€ 146,904 Equity 2022: € 146,904 First fiscal year in the series	€ 162,157 Equity 2023: € 162,157 ▲ 10% vs 2022 (€ 146,904) Favourable step	€ 190,473 Equity 2024: € 190,473 ▲ 17% vs 2023 (€ 162,157) Favourable step	€ 227,556 Equity 2025: € 227,556 ▲ 19% vs 2024 (€ 190,473) Favourable step	▲ 19%
Total debts	€ 740,690 Total debts 2022: € 740,690 First fiscal year in the series	€ 678,177 Total debts 2023: € 678,177 ▼ 8% vs 2022 (€ 740,690) Favourable step	€ 616,053 Total debts 2024: € 616,053 ▼ 9% vs 2023 (€ 678,177) Favourable step	€ 621,730 Total debts 2025: € 621,730 ▲ 1% vs 2024 (€ 616,053) Unfavourable step	▲ 1%
Cash	€ 31,643 Cash 2022: € 31,643 First fiscal year in the series	€ 15,485 Cash 2023: € 15,485 ▼ 51% vs 2022 (€ 31,643) Unfavourable step	€ 12,735 Cash 2024: € 12,735 ▼ 18% vs 2023 (€ 15,485) Unfavourable step	€ 25,326 Cash 2025: € 25,326 ▲ 99% vs 2024 (€ 12,735) Favourable step	▲ 99%
Land & buildings	€ 382,576 Land & buildings 2022: € 382,576 First fiscal year in the series	€ 362,976 Land & buildings 2023: € 362,976 ▼ 5% vs 2022 (€ 382,576) Unchanged	€ 343,376 Land & buildings 2024: € 343,376 ▼ 5% vs 2023 (€ 362,976) Unchanged	€ 323,776 Land & buildings 2025: € 323,776 ▼ 6% vs 2024 (€ 343,376) Unchanged	▼ 6%
Retained profit	€ 66,904 Retained profit 2022: € 66,904 First fiscal year in the series	€ 82,157 Retained profit 2023: € 82,157 ▲ 23% vs 2022 (€ 66,904) Favourable step	€ 110,473 Retained profit 2024: € 110,473 ▲ 34% vs 2023 (€ 82,157) Favourable step	€ 147,556 Retained profit 2025: € 147,556 ▲ 34% vs 2024 (€ 110,473) Favourable step	▲ 34%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 7,294 Dividend 2023: € 7,294 Unchanged (€ 0) Unchanged	€ 4,000 Dividend 2024: € 4,000 ▼ 45% vs 2023 (€ 7,294) Unchanged	€ 14,000 Dividend 2025: € 14,000 ▲ 250% vs 2024 (€ 4,000) Unchanged	▲ 250%
Bank debt	€ 618,209 Bank debt 2022: € 618,209 First fiscal year in the series	€ 562,867 Bank debt 2023: € 562,867 ▼ 9% vs 2022 (€ 618,209) Favourable step	€ 506,947 Bank debt 2024: € 506,947 ▼ 10% vs 2023 (€ 562,867) Favourable step	€ 450,439 Bank debt 2025: € 450,439 ▼ 11% vs 2024 (€ 506,947) Favourable step	▼ 11%
Balance sheet total	€ 887,594 Balance sheet total 2022: € 887,594 First fiscal year in the series	€ 840,334 Balance sheet total 2023: € 840,334 ▼ 5% vs 2022 (€ 887,594) Unchanged	€ 806,526 Balance sheet total 2024: € 806,526 ▼ 4% vs 2023 (€ 840,334) Unchanged	€ 849,286 Balance sheet total 2025: € 849,286 ▲ 5% vs 2024 (€ 806,526) Unchanged	▲ 5%
Employees (FTE)	-	0.6 Employees (FTE) 2023: 0.6 First fiscal year in the series	0.6 Employees (FTE) 2024: 0.6 Unchanged (0.6) Unchanged	1 Employees (FTE) 2025: 1 ▲ 0.4 vs 2024 (0.6) Unchanged	▲ 0.4

Key figures of Hove Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Hove Pharma?

What happened at Hove Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 24, 2026 New annual accounts for financial year 2025: profit of € 51,083 (▲ 58% vs 2024). filed late Source: NBB ↗
Jan 1, 2020 New establishment in Hove. KBO
Nov 18, 2019 Start of the company according to the CBE. KBO

In short

From € 59,044 loss in 2022 to € 51,083 profit in 2025.

Paid € 14,988 in corporate taxes since 2022.

Best year ever: 2025, with € 51,083 profit.

On average € 198,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

JKS Hove BV APG Management BV

Hove Pharma

Behind Hove Pharma are JKS Hove BV and APG Management BV.

Directors

According to the 2025 annual accounts

JKS Hove BV

Director · represented by Balduyck Sarah

APG Management BV

Director · represented by Hoeck Ann

Establishments

Establishment units

Physical locations of this company

Registered office

Kapelstraat 12

2540 Hove

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

PITCH-IT

€ 73,490 gross margin · 2025

Vereniging van Mede-eigenaars van het gebouw Kapelstraat 12 te Hove

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS hovepharma.be

Canonical: https://www.hovepharma.be

Technologies

Advanced Custom FieldsFacebook PixelGoogle AnalyticsGoogle App EngineGoogle Tag ManagerLodashPWAReactWixlazysizes

Hosting & Email

Email provider

one.com Mail

Hosting

WIX_COM, IL

Website info

HTTPS Ja

Languages NL

Features

Webshop Ads

Security

✓ HTTPS

✗ SPF

✗ DMARC

Network

✓ Load balancing

Details

Company number: 0737.798.331
VAT number: BE 0737.798.331
Registered office: Kapelstraat 12, 2540 Hove
Names & denominations: Hove Pharma
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 18 November 2019
Peppol: Active · Active since 21 Nov 2025
Contact: hovepharma.be 03 455 25 28
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗